The beneficial effects of SGLT2 inhibitors on heart failure in patients with diabetes mellitus type 2 prompted the inception of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction) trials [45, 46]. Here, SLC5A2 is linked to diabetes mellitus.